Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of Ingenjörsfirman Gösta Schelin, Ventilationshygien Stockholm and Pactor Luftbehandling
Mandate

Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of Ingenjörsfirman Gösta Schelin, Ventilationshygien Stockholm and Pactor Luftbehandling

March 31, 2021 Employment and Benefits M&A Real Estate and Construction

Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of Ingenjörsfirman Gösta Schelin Aktiebolag, Ventilationshygien Stockholm AB and Pactor Luftbehandling Aktiebolag.

The companies provide services within design, installation and service linked to indoor climate and are based in Stockholm. Together, the companies have a turnover of approximately SEK 250 million. The transaction is subject to customary regulatory approvals.

Vinge’s team consisted of partner Christina Kokko together with Karl Klackenberg, Hannah Kajlinger and Carl Fredrik Wachtmeister (M&A), Isak Willborg (Construction), Elin Broman (Employment) and Frida Ställborn (Real Estate).

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025